We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
- Authors
Gao, J; He, Q; Subudhi, S; Aparicio, A; Zurita-Saavedra, A; Lee, D H; Jimenez, C; Suarez-Almazor, M; Sharma, P
- Abstract
Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.
- Subjects
PROSTATE cancer patients; PROSTATE cancer treatment; DRUG side effects; IPILIMUMAB; T cells; CLINICAL trials; IMMUNOTHERAPY; THERAPEUTICS; PHYSIOLOGY
- Publication
Oncogene, 2015, Vol 34, Issue 43, p5411
- ISSN
0950-9232
- Publication type
Article
- DOI
10.1038/onc.2015.5